Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction

Inclusion Criteria:

1. Written informed consent for the extension must be obtained before any assessment isperformed.

2. Patients who have completed PARADIGM-HF (protocol CLCZ696B2314) and are able to besafely enrolled into the open-label trial as judged by the investigator.

Exclusion Criteria:

1. Use of other investigational drugs at the time of enrollment, or within 30 days or 5half-lives of enrollment, whichever is longer

2. History of hypersensitivity or allergy to any of the study drugs, drugs of similarchemical classes, ACEIs, ARBs, or NEP inhibitors as well as known or suspectedcontraindications to LCZ696

3. Known history of angioedema

4. Requirement of simultaneous treatment with both ACEIs and ARBs

5. Current acute decompensated HF (exacerbation of chronic HF manifested by signs andsymptoms that may require intravenous therapy)

6. Symptomatic hypotension and/or a SBP < 100 mmHg at Visit 1 (screening)

7. Estimated GFR < 30 mL/min/1.73m^2 as measured by the simplified MDRD formula at Visit 1 (screening)

8. Presence of bilateral renal artery stenosis

9. Serum potassium > 5.2 mmol/L at Visit 1 (screening)

10. Evidence of hepatic disease as determined by any one of the following: AST or ALTvalues exceeding 3 x ULN at Visit 1, history of hepatic encephalopathy, history ofesophageal varices, or history of portacaval shunt

11. Pregnant or nursing (lactating) women

12. Women of child-bearing potential

13. Any condition, not identified in the protocol, that in the opinion of the investigatoris likely to prevent the patient from safely tolerating LCZ696 or complying with therequirements of the study.